CorMedix (CRMD) Competitors $12.80 -0.90 (-6.57%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$12.88 +0.07 (+0.59%) As of 09/4/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRMD vs. ADMA, AAPG, PCVX, PTCT, LNTH, ACLX, ZLAB, AKRO, MIRM, and MENSShould you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), Vaxcyte (PCVX), PTC Therapeutics (PTCT), Lantheus (LNTH), Arcellx (ACLX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Mirum Pharmaceuticals (MIRM), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. CorMedix vs. Its Competitors ADMA Biologics Ascentage Pharma Group International Vaxcyte PTC Therapeutics Lantheus Arcellx Zai Lab Akero Therapeutics Mirum Pharmaceuticals Jyong Biotech ADMA Biologics (NASDAQ:ADMA) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability. Do analysts rate ADMA or CRMD? ADMA Biologics presently has a consensus price target of $27.67, suggesting a potential upside of 63.61%. CorMedix has a consensus price target of $17.33, suggesting a potential upside of 35.42%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33CorMedix 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more volatility & risk, ADMA or CRMD? ADMA Biologics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Do institutionals and insiders hold more shares of ADMA or CRMD? 75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by insiders. Comparatively, 5.3% of CorMedix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor ADMA or CRMD? In the previous week, CorMedix had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 12 mentions for CorMedix and 9 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.75 beat CorMedix's score of 0.94 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CorMedix 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ADMA or CRMD more profitable? ADMA Biologics has a net margin of 44.06% compared to CorMedix's net margin of 42.11%. CorMedix's return on equity of 42.73% beat ADMA Biologics' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics44.06% 41.01% 28.47% CorMedix 42.11%42.73%34.19% Which has higher valuation & earnings, ADMA or CRMD? ADMA Biologics has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M9.46$197.67M$0.8619.66CorMedix$43.47M21.98-$17.93M$0.7517.07 SummaryADMA Biologics beats CorMedix on 9 of the 16 factors compared between the two stocks. Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRMD vs. The Competition Export to ExcelMetricCorMedixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio17.0720.8975.9926.43Price / Sales21.98458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book9.149.9310.916.06Net Income-$17.93M-$53.38M$3.29B$266.28M7 Day Performance-13.69%0.63%0.18%-0.32%1 Month Performance6.14%6.31%6.26%3.44%1 Year Performance124.56%11.63%51.54%23.11% CorMedix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRMDCorMedix3.551 of 5 stars$12.80-6.6%$17.33+35.4%+123.0%$1.02B$43.47M17.0730Positive NewsShort Interest ↑ADMAADMA Biologics3.9415 of 5 stars$17.01-4.4%$27.67+62.6%+0.2%$4.06B$474.17M19.78530Positive NewsAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.04B$134.35M0.00600Positive NewsGap DownPCVXVaxcyte2.8444 of 5 stars$30.45-5.7%$136.50+348.3%-70.5%$3.95BN/A-7.41160News CoveragePositive NewsPTCTPTC Therapeutics3.9518 of 5 stars$49.30-2.5%$69.15+40.3%+72.7%$3.92B$1.76B7.071,410Analyst ForecastLNTHLantheus4.8892 of 5 stars$56.16-3.5%$105.50+87.9%-49.4%$3.82B$1.52B14.94700Short Interest ↓ACLXArcellx2.2105 of 5 stars$68.49-3.9%$114.31+66.9%+10.2%$3.80B$107.94M-20.0380News CoveragePositive NewsZLABZai Lab2.5648 of 5 stars$34.03-2.9%$56.35+65.6%+51.8%$3.78B$427.80M-16.681,869Gap DownAKROAkero Therapeutics3.9277 of 5 stars$47.03-4.5%$81.57+73.4%+67.4%$3.76BN/A-23.5230News CoveragePositive NewsAnalyst ForecastInsider TradeMIRMMirum Pharmaceuticals3.3256 of 5 stars$71.81+0.4%$74.13+3.2%+77.5%$3.61B$336.89M-59.35140Positive NewsMENSJyong BiotechN/A$47.00+2.2%N/AN/A$3.57BN/A0.0031News CoverageGap Down Related Companies and Tools Related Companies ADMA Alternatives AAPG Alternatives PCVX Alternatives PTCT Alternatives LNTH Alternatives ACLX Alternatives ZLAB Alternatives AKRO Alternatives MIRM Alternatives MENS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRMD) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRMD Stock Alerts